BRIGHT MINDS BIOSCIENCES Logo
CA10919W1086
A2QN4Y
DRUG

BRIGHT MINDS BIOSCIENCES

Previsión

El precio objetivo medio de los analistas es de 100,78 € (+420,02 %). La mediana es de 132,04 € (+581,32 %).

Comprar
  5
Mantener
  0
Vender
  0

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • Bright Minds Biosciences raises $175 million through placement of common shares

    Bright Minds Biosciences placed 1,945,000 common shares at $90.00 each, generating gross proceeds of $175.05 million. The syndicate banks were granted a 30-day overallotment option for up to 291,750 additional shares. The funds are intended to finance clinical trials (including the start of phase 1 for BMB-105), research and development of earlier programs, and general corporate purposes. » Más en de.investing.com


  • Bright Minds Biosciences sets price for share offering at $90

    Bright Minds Biosciences has set the price for a public offering of 1,945,000 common shares at $90.00 per share and expects gross proceeds of about $175.05 million. The underwriters were granted a 30-day option to purchase up to 291,750 additional shares at the same price; closing is expected on January 9, 2026. The proceeds are intended to fund clinical trials for several drug candidates; the company has simultaneously ended its at-the-market program. Analysts mostly rate the stock as "Buy," and the share price and market capitalization have risen sharply after a strong rally. » Más en de.investing.com


  • Bright Minds Biosciences plans public offering of $100 million

    Bright Minds Biosciences announced a public offering of common stock and pre-funded warrants totaling $100 million and granted the underwriters a 30-day option to purchase up to 15% of the offered common stock. Proceeds are intended to fund clinical trials for drugs targeting absence seizures, DEE and Prader‑Willi syndrome, as well as Phase 1 studies for BMB‑105, earlier-stage research and general corporate purposes. The offering is being made under an F-3 registration; Jefferies, TD Cowen, Piper Sandler and Cantor are serving as joint book-running managers. The company reports a strong balance sheet with more cash than debt and a current ratio of 36.1. » Más en de.investing.com


  • Bright Minds Biosciences stock rises after positive phase‑2 data on BMB‑101

    The stock of Bright Minds Biosciences rose about 5% after positive topline results from the phase‑2 BREAKTHROUGH study of the selective 5‑HT2C agonist BMB‑101 in epilepsy‑associated disorders. In the 24‑patient study, median seizure frequency in absence epilepsy fell by 73.1% (p=0.012) and severe motor seizures in DEE patients by 63.3%. BMB‑101 also significantly improved REM sleep, was mostly well tolerated and showed no treatment‑related serious adverse events. Bright Minds is preparing global registration trials for DEE and absence epilepsy and plans a study in Prader‑Willi syndrome in Q1 2026. » Más en de.investing.com


  • Bright Minds launches Prader‑Willi program and nominates BMB-105 as clinical candidate

    Bright Minds has launched a Prader‑Willi syndrome (PWS) program and nominated BMB-105 as a new clinical candidate. The company is starting the double‑blind, randomized phase‑2a NOVA study with BMB-101 to evaluate efficacy and safety in PWS patients and plans a parallel randomized, placebo‑controlled phase‑1 study of BMB-105 in healthy volunteers. BMB-101 has shown good tolerability so far in epilepsy studies, with top‑line data expected in January 2026; Bright Minds aims to accelerate time to market by roughly one year with BMB-105. » Más en de.investing.com

Datos financieros

En el último trimestre, BRIGHT MINDS BIOSCIENCES tuvo unos ingresos de 0 € y un beneficio neto de -1,52 M €

(EUR) junio de 2026
YoY
Ingresos 0 -
Beneficio bruto -12,32 mil -
Beneficio neto -1,52 M 53,56 %
EBITDA -7,22 M 121,62 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
189,71 M €
Número de acciones
9,86 M
Máximo/mínimo de 52 semanas
112,69 € - 15,84 €
Dividendos No
Beta
0,09
Ratio P/E
-9,97
Ratio PEG
0,13
Ratio P/B
0,92
Ratio P/S
0,00

Perfil de la empresa

Bright Minds Biosciences Inc., una empresa de biociencias en fase preclínica, desarrolla medicamentos basados en 5-HT (serotonina) para mejorar la vida de pacientes con enfermedades graves que alteran profundamente la vida. Su cartera de agonistas selectivos de los receptores 5-HT comprende 5-HT2C, 5-HT2A y 5-HT2C/A para el tratamiento de la epilepsia, el dolor y la neuropsiquiatría. La compañía mantiene una colaboración con los National Institutes of Health para el tratamiento de la epilepsia; con la University of Texas Medical Branch para tratar trastornos del control de impulsos, como el trastorno por atracón; y con el Medical College of Wisconsin. La empresa se constituyó en 2019 y tiene su sede en Vancouver, Canadá.

Nombre
BRIGHT MINDS BIOSCIENCES
CEO
Ian McDonald
Sede New York, ny
Canadá
Sitio web
Sector
Materiales
Industria
Productos químicos
Salida a bolsa
22/03/2021
Empleados 26

Símbolos bursátiles

Bolsa Símbolo
NASDAQ
DRUG
🍪

Parqet  usa cookies. Más información